Key facts
- It has raised $44.6M; the latest was Later Stage VC in Feb 2026.
- Notable investors include Morningside Group, Lapam Capital, Beijing Zhongguancun Venture Capital Development, Suzhou Zhongxin Innovation Investment Management, Youchoose Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for MaxiNovel
- ·The full record, as it builds
Funding rounds
No funding rounds for MaxiNovel are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MaxiNovel
Developer of biotechnology focused on molecule therapeutics intended for various types of threatening cancer. The company offers research-driven drug discovery development capabilities and a portfolio of targeted and immune-related therapeutic approaches focused on cancer biology, disease mechanisms,s and clinical needs, enabling healthcare systems, medical researchers, and patients to address disease burden and insufficient existing care options.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2016
- Website
- maxinovel.com/
- Ownership
- Privately Held (backing)
MaxiNovel doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MaxiNovel shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MaxiNovel in its N-PORT filings yet. We sweep new filings monthly.